Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7.